Ausgabe 1/2019
Inhalt (24 Artikel)
Chemotherapy and cognition: comprehensive review on doxorubicin-induced chemobrain
Sara Emad El-Agamy, Amal Kamal Abdel-Aziz, Ahmed Esmat, Samar S. Azab
Uveal melanoma: physiopathology and new in situ-specific therapies
E. B. Souto, A. Zielinska, M. Luis, C. Carbone, C. Martins-Gomes, S. B. Souto, A. M. Silva
Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer
Mayumi Kobayashi-Kato, Mayu Yunokawa, Seiko Bun, Naoyuki Miyasaka, Tomoyasu Kato, Kenji Tamura
Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial
Arnauld C. Verschuur, Viera Bajčiová, Leo Mascarenhas, Reza Khosravan, Xun Lin, Antonella Ingrosso, Katherine A. Janeway
Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics
Hitesh B. Mistry, Gabriel Helmlinger, Nidal Al-Huniti, Karthick Vishwanathan, James Yates
Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer
Zhuanglin Li, Mingxue Wang, Deling Yu, Wenting Luo, Jianmin Fang, Changjiang Huang, Xuejing Yao
Pharmacokinetics and safety of lobaplatin plus etoposide in Chinese men older than 65 years with extensive-stage small cell lung cancer: a phase II clinical trial
Jianhua Chen, Bingyang Liu, Fang Zhang, Weiping Cui, Peng Zhang
Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer
Xiaoying Chen, Cheryl Li, Reginald Ewesuedo, Donghua Yin
A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [14C]-labeled idasanutlin and an intravenous tracer dose of [13C]-labeled idasanutlin in a single cohort of patients with solid tumors
Zsuzsanna Pápai, Lin-Chi Chen, Daniel Da Costa, Steven Blotner, Faye Vazvaei, Michelle Gleave, Russell Jones, Jianguo Zhi
Orally administered salecan ameliorates methotrexate-induced intestinal mucositis in mice
Yan Gao, Qi Sun, Xiao Yang, Weiling Lu, Yang Zhao, Wenhao Ge, Yunxia Yang, Xi Xu, Jianfa Zhang
Treatment with selenium-enriched Saccharomyces cerevisiae UFMG A-905 partially ameliorates mucositis induced by 5-fluorouracil in mice
Bárbara A. A. Porto, Cinthia F. Monteiro, Éricka L. S. Souza, Paola C. L. Leocádio, Jacqueline I. Alvarez-Leite, Simone V. Generoso, Valbert N. Cardoso, Camila M. Almeida-Leite, Daniel A. Santos, Julliana R. A. Santos, Jacques R. Nicoli, Enrica Pessione, Flaviano S. Martins
Clinical characteristics, treatment patterns and outcomes of patients older than 80 years diagnosed with DLBCL in China over a 10-year period
Zhan Shi, Xi Tang, Qianwen Shen, Jiayan Chen, Fei Liu, Xi Chen, Jingwen Wang, Jie Zhuang
Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer
Malmaruha Arasaratnam, Megan Crumbaker, Atul Bhatnagar, Matthew J. McKay, Mark P. Molloy, Howard Gurney
Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting
Kazuki Tanaka, Naoki Inui, Masato Karayama, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto, Yutaro Nakamura, Hideki Kusagaya, Shun Matsuura, Tomohiro Uto, Dai Hashimoto, Takashi Matsui, Kazuhiro Asada, Takafumi Suda
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as a first-line concurrent chemotherapy regimen in nasopharyngeal carcinoma: a prospective, multi-institution, randomized controlled phase II study
Xiang-Yun Kong, Jian-Xun Lu, Xin-Wen Yu, Jian Zhang, Qian-Lan Xu, Rong-Jun Zhang, Jing-Lin Mi, Shu-Fang Liao, Jin-Fang Fan, Xiao-Li Qin, Da-Cheng Yao, Hua-Ying Tang, Wei Jiang
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias
Tara L. Lin, Laura F. Newell, Robert K. Stuart, Laura C. Michaelis, Eric Rubenstein, Helen S. Pentikis, Timothy Callahan, Donna Alvarez, Barry D. Liboiron, Lawrence D. Mayer, Qi Wang, Kamalika Banerjee, Arthur C. Louie
Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer
Dan Lu, Chunze Li, Matthew Riggs, Daniel Polhamus, Jonathan French, Priya Agarwal, Shang-Chiung Chen, Shweta Vadhavkar, Monika Patre, Alexander Strasak, Angelica Quartino, Jin Yan Jin, Sandhya Girish
Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to Gemcitabine in bladder cancer
Bo Li, Dalon Xie, Hui Zhang
Renin–angiotensin system inhibitors for countering proteinuria induced by angiogenesis inhibitors: a retrospective observational analysis
Toshinori Hirai, Yukari Shuji, Megumi Takiyama, Kazuhiko Hanada, Toshimasa Itoh
Clinical implications of an analysis of pharmacokinetics of crizotinib coadministered with dexamethasone in patients with non-small cell lung cancer
Swan Lin, Dana J. Nickens, Maulik Patel, Keith D. Wilner, Weiwei Tan
Qualitative and quantitative variations in liver function thresholds among clinical trials in cancer: a need for harmonization
Edwin Wang, Fei Song, Jessica K. Paulus, Douglas Hackenyos, Paul Mathew
Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand–foot syndrome: a newly recognized toxicity
Daniel F. Pease, Bruce A. Peterson, Scott Gilles, Maria K. Hordinsky, Kimberly A. Bohjanen, Keith M. Skubitz
Efficacy of immunotherapy, gut microbiota and impact of antibiotic use: are there confounding factors?
G. Milano
Stress resilience and survival among cancer patients: is there any absolute truth?
Raffaella Mormile